Abstract
Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they’re relatively cell-, receptor- and energy-independent, CPPs have unique advantages in facilitating drugs entry into cells. This paper briefly reviews the discovery, mechanism and classification of CPPs, and especially focuses on the specific limitations of CPPs and their potential applications for tumor-targeted delivery of biologically active molecules, imaging agents and carriers.
Keywords: Cell penetrating peptides, tumor, targeting.
Graphical Abstract
Current Cancer Drug Targets
Title:Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging
Volume: 15 Issue: 4
Author(s): Weiqin Wang, Sarra Abbad, Zhenhai Zhang, Shu Wang, Jianping Zhou and Huixia Lv
Affiliation:
Keywords: Cell penetrating peptides, tumor, targeting.
Abstract: Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they’re relatively cell-, receptor- and energy-independent, CPPs have unique advantages in facilitating drugs entry into cells. This paper briefly reviews the discovery, mechanism and classification of CPPs, and especially focuses on the specific limitations of CPPs and their potential applications for tumor-targeted delivery of biologically active molecules, imaging agents and carriers.
Export Options
About this article
Cite this article as:
Wang Weiqin, Abbad Sarra, Zhang Zhenhai, Wang Shu, Zhou Jianping and Lv Huixia, Cell-penetrating Peptides for Cancer-targeting Therapy and Imaging, Current Cancer Drug Targets 2015; 15 (4) . https://dx.doi.org/10.2174/1568009615666150211104524
DOI https://dx.doi.org/10.2174/1568009615666150211104524 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NSAIDs and Chemoprevention
Current Cancer Drug Targets Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma
Letters in Drug Design & Discovery Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry Current Inhibitors of Checkpoint Kinase 2
Current Medicinal Chemistry Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Preparation, Characterization and Drug Release of Salicylic Acid Loaded Porous Electrospun Nanofibers
Recent Patents on Nanotechnology Anti-glioma Effects of Caffeic Acid Phenethyl Ester and Dasatinib Combination Therapy in an in vivo Rat Glioma Model
Anti-Cancer Agents in Medicinal Chemistry Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Monocarboxylate Transporter 1 in Brain Diseases and Cancers
Current Drug Metabolism Drug Targeting to the Brain - A Review
Current Nanoscience The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Tumour Gene Therapy Monitoring Using Magnetic Resonance Imaging and Spectroscopy
Current Gene Therapy